Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2B | Q13224 | 1/20 | 0.47 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | AMPD2 | Q01433 | 6/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | GRM6 | O15303 | 1/20 | 0.34 |
| ▸ | ELANE | P08246 | 1/20 | 0.34 |
| ▸ | ACE | P12821 | 1/20 | 0.34 |
| ▸ | REN | P00797 | 1/20 | 0.33 |
| ▸ | CTSD | P07339 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22087702 | 0.82 | GRIN2B (0.41) | GRIN2BGRIN2CCYP2D6ALDH1A1AMPD2 | |
| SCHEMBL19853347 | 0.82 | GRIN2B (0.41) | GRIN2BGRIN2CCYP2D6ALDH1A1AMPD2 | |
| SCHEMBL19853465 | 0.80 | GRIN2B (0.52) | GRIN2BGRIN2C | |
| SCHEMBL22086433 | 0.77 | GRIN2B (0.56) | GRIN2BGRIN2C | |
| SCHEMBL18556507 | 0.75 | GRIN2B (0.51) | GRIN2BGRIN2CCYP2D6ALDH1A1TSHR | |
| SCHEMBL21234102 | 0.75 | GRIN2B (0.43) | GRIN2BGRIN2CCYP2D6ALDH1A1AMPD2 | |
| SCHEMBL22087525 | 0.75 | GRIN2B (0.54) | GRIN2BGRIN2C | |
| SCHEMBL19229626 | 0.74 | GRIN2B (0.49) | GRIN2BGRIN2CCYP2D6ALDH1A1KMT2A | |
| SCHEMBL17712366 | 0.74 | GRIN2B (0.49) | GRIN2BGRIN2CCYP2D6ALDH1A1KMT2A | |
| SCHEMBL23467759 | 0.74 | GRIN2B (0.36) | GRIN2BGRIN2CCYP2D6ALDH1A1AMPD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220273629-A1 | METHODS OF TREATING DISORDERS ASSOCIATED WITH ELEVATED LEVELS OF ANTIBODIES THAT INTERACT WITH THE NMDA RECEPTOR | TENACIA BIOTECHNOLOGY (HONG KONG) CO., LIMITED (HK) | 2022-09-01 | — | — | US | disclosed |
| US-11028095-B2 | Spiro-lactam and bis-spiro-lactam NMDA receptor modulators and uses thereof | APTINYX INC. (US) | 2021-06-08 | — | — | US | disclosed |
| WO-2021021996-A1 | METHODS OF TREATING DISORDERS ASSOCIATED WITH ELEVATED LEVELS OF ANTIBODIES THAT INTERACT WITH THE NMDA RECEPTOR | APTINYX INC. (US) | 2021-02-04 | — | — | WO | disclosed |
| US-20200181159-A1 | SPIRO-LACTAM AND BIS-SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | TENACIA BIOTECHNOLOGY (HONG KONG) CO., LIMITED (HK) | 2020-06-11 | — | — | US | disclosed |
| WO-2018026792-A1 | SPIRO-LACTAM AND BIS-SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | APTINYX INC. (US) | 2018-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200181159-A1 | SPIRO-LACTAM AND BIS-SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | GRIN1, GRIN2A, GRIN2C | GRIN2B 4/4885GRIN2C 3/4885CYP2D6 492/4885 |
| US-20220273629-A1 | METHODS OF TREATING DISORDERS ASSOCIATED WITH ELEVATED LEVELS OF ANTIBODIES THAT INTERACT WITH THE NMDA RECEPTOR | GRIN2A, GRIN2B, GRIN1 | GRIN2B 2/4885GRIN2C 4/4885CYP2D6 3390/4885 |
| US-11028095-B2 | Spiro-lactam and bis-spiro-lactam NMDA receptor modulators and uses thereof | GRIN1, GRIN2A, GRIN2C | GRIN2B 4/4885GRIN2C 3/4885CYP2D6 492/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.